Drugs Made In America Acquisition Corp. Units (DMAAU) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Drugs Made In America Acquisition Corp. Units (DMAAU) has a cash flow conversion efficiency ratio of -0.001x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-125.18K) by net assets ($232.64 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See DMAAU equity financing ratio to measure how much of total assets are equity-financed.
Drugs Made In America Acquisition Corp. Units - Cash Flow Conversion Efficiency Trend (2024–2025)
This chart illustrates how Drugs Made In America Acquisition Corp. Units's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check DMAAU operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Drugs Made In America Acquisition Corp. Units Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Drugs Made In America Acquisition Corp. Units ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nanjing Chixia Development Co Ltd
SHG:600533
|
0.002x |
|
D. Boral Acquisition I Corp. Class A Ordinary Shares
NASDAQ:DBCA
|
-0.001x |
|
Edda Wind ASA
OL:EWIND
|
0.018x |
|
Centurion Acquisition Corp.
NASDAQ:ALF
|
0.000x |
|
Bharat Bijlee Limited
NSE:BBL
|
-0.017x |
|
Cohen Dev
TA:CDEV
|
0.075x |
|
Beijing Piesat Information Technology Co Ltd
SHG:688066
|
0.072x |
|
Beijing ZEHO Waterfront Ecological Environment Treatment Co Ltd
SHG:605069
|
-0.050x |
Annual Cash Flow Conversion Efficiency for Drugs Made In America Acquisition Corp. Units (2024–2025)
The table below shows the annual cash flow conversion efficiency of Drugs Made In America Acquisition Corp. Units from 2024 to 2025. For the full company profile with market capitalisation and key ratios, see Drugs Made In America Acquisition Corp. (DMAAU) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $232.64 Million | $-539.19K | -0.002x | -100.00% |
| 2024-12-31 | $-244.85 | $-172.26K | 703.553x | -- |
About Drugs Made In America Acquisition Corp. Units
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in Fort Lauderdale, Florida.